BioSpace News Archive

- Application Submitted for the Treatment of Partial Seizures in Epilepsy Patients - Eton’s Patent-Pending Product Addresses Significant Unmet Need for a Liquid Formulation of Zonisamide - Application is Eton’s Sixth Drug Application Under FDA Review

Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that Krish S. Krishnan, chairman and chief executive officer, will be participating in a fireside chat at the William Blair BioTech Conference taking place August 4-6, 2020. Details for the presentation are as follows: William Blair BioTech Conf

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in August

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on August 6, 2020, to provide a business update and review the company’s financial results for the second quarter ended June 30, 2020. To access the live c

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to host a conference call on Thursday, August 06, 2020, at 8:30 a.m. Eastern Time to discuss its financial results for the second quarter and recent operational highlights. Individuals may participate in the l

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate in virtual fireside chats at the following investor conferences: William Blair Biotech Focus Conference 2020 on August 6 at 3:00 p.m. ET; Wedbush PacGrow Healthcare Virtual Conference on August 11 at 2:55 p.m. ET; and Canaccord Genuity 40 th Annual Growth Virtual Conference on August 13 at 1:30

SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced that Radek Špíšek , chief executive officer of SOTIO, will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020. Please click the following link to register: https://lifesci.events/SummerSymposium Presentation Details: Date: A

Presentation of positive clinical data at EHA 2020 supporting the ongoing Phase 3 trial in WHIM syndrome Initial data expected later this year from Phase 1b clinical trial in Waldenström’s macroglobulinemia Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today reporte

Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced the appointment of Michael Overdorf as Chief Business Officer. “I’m pleased to welcome Michael to our organization as we look to leverage his expertise across the organization, and in particular with regard to our

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11 to 13, 2020.